The present invention relates to a composition comprising, preferably consisting of, (i) a single empty liposome, wherein said single empty liposome is selected from (a) an empty liposome consisting of sphingomyelin and cholesterol, wherein the amount of cholesterol is at least 20% (weight per weight); or (b) an empty liposome consisting of sphingomyelin; or (ii) a mixture of empty liposomes; wherein said mixture of empty liposomes comprises (a) a first empty liposome consisting of sphingomyelin and cholesterol, wherein the amount of cholesterol is at least 20% (weight per weight); and (b) a second empty liposome consisting of sphingomyelin; for use in a method of treating or preventing a viral infection in a mammal, preferably in a human.

A composition comprising a hydrogen peroxide source and at least one metal halide. The hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide. The means for producing hydrogen peroxide comprises at least one oxidoreductase and at least one oxidoreductase substrate. The oxidoreductase substrate comprises at least one sugar, said sugar located within the composition. The composition is held under conditions that render the components inactive until rehydrated.

This invention refers to a probiotic composition consisting of the bacteria Lactobacillus rhamnosus, Lactobacillus casei and Bifidobacterium longum, preferably of the strains L. rhamnosus CECT8361, L. casei CECT9104 and B. longum CECT7347, and its use as an antioxidant. This composition is particularly useful in the treatment and/or prevention of damage, at the molecular level, caused by oxidative stress, preferably during high intensity physical exercise.

The present invention relates to a Bicycle toxin conjugate BT5528, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof.

The present invention provides ophthalmic pharmaceutical compositions of the compound of Formula (I).

##STR(I)##

The present invention provides ophthalmic pharmaceutical compositions of the compound of Formula (I).

##STR(I)##

Disclosed herein are compounds, compositions, and methods for modulating the A.sub.2A adenosine receptor with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the A.sub.2A adenosine receptor, such as cancer, with A.sub.2A adenosine receptor antagonists.

Disclosed herein are compounds, compositions, and methods for modulating the A.sub.2A adenosine receptor with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the A.sub.2A adenosine receptor, such as cancer, with A.sub.2A adenosine receptor antagonists.

The present invention relates to an ophthalmic preparation containing an active ingredient selected from 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol compound or a pharmaceutically acceptable salt thereof. The eye drop according to the present invention is excellent in stability and safety and shows an excellent effect on prevention or treatment of eye diseases in such a way that an active ingredient thereof reaches a posterior segment of an eyeball simply through instillation rather than a direct injection into an eyeball.

The disclosure includes methods of preventing, ameliorating, and/or treating ischemia-reperfusion injury (IRI), including but not limited to post brain stroke, using a MAP3K2/MAP3K3 inhibitor. In another aspect, the present disclosure relates to methods of preventing, ameliorating, and/or treating a lung injury related to a coronavirus infection, acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS) using a MAP3K2/MAP3K3 inhibitor. The disclosure further comprises compositions, and kits comprising compositions useful within the disclosure.